Sales & Marketing Sponsored 12 Questions with Jim Sage Jim Sage is a seasoned global pharmaceutical executive with extensive marketing, commercial, and leadership experience across major therapeutic areas.
R&D Sponsored 12 Questions with Phil Davey Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada.
R&D Sponsored 12 Questions With Trenton M. Johnson Find out more about Senior Director of CMC Portfolio Management, Thermo Fisher Scientific, Trenton M. Johnson in a new 12 Questions With.
Digital Sponsored 12 Questions with Felix Faber Mindpeak's Felix Faber is an award-winning entrepreneur and computer scientist with a track record of founding companies.
Oncology Sponsored 12 Questions with Rick Coope Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.
Sales & Marketing Sponsored 12 Questions with Chris Venezia As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.